首页 / 院系成果 / 成果详情页

Combination of entecavir with thymosin alpha-1 in HBV-related compensated cirrhosis: a prospective multicenter randomized open-label study 期刊论文

编号：

7452ea2e-6ed4-42c4-9f5f-82c1b27a6216
作者：

Wu, Xiaoning^[1];Shi, Yiwen^[1];Zhou, Jialing^[1];Sun, Yameng^[1];Piao, Hongxin^[2];Jiang, Wei(蒋炜)^[3]Ma, Anlin^[4];Chen, Yongpeng^[5];Xu, Mingyi^[6];Xie, Wen^[7];Cheng, Jun^[8];Xie, Shibin^[9];Shang, Jia^[10];Cheng, Jilin(程计林)^[11]Xie, Qing^[12];Ding, Huiguo^[13];Zhang, Xuqing^[14];Bai, Lang^[15];Zhang, Mingxiang^[16];Wang, Bingqiong^[1];Chen, Shuyan^[1];Ma, Hong^[1];Ou, Xiaojuan^[1];Jia, Jidong^[1];You, Hong^[1];
语种：

English
期刊：

EXPERT OPINION ON BIOLOGICAL THERAPY ISSN：1471-2598 2018 年 18 卷 (61 - 69)
收录：
关键词：

Hepatitis B virus liver cirrhosis hepatocellular carcinoma immune regulator thymosin alpha-1 Ta-1
摘要：

Background: Thymosin alpha-1 (Ta-1) suppresses HBV viral replication, while the evidence of combination effect with nucleoide is still limited. We aimed to investigate the efficacy and safety of combination therapy of Ta-1 with entecavir (ETV) in patients with compensated liver cirrhosis.Research design and methods: A total of 690 patients were randomized to receive Ta-1 plus ETV (n=351) or ETV monotherapy (n=339) for 52weeks after 26weeks of ETV treatment, followed by continued entecavir therapy. The primary endpoint was defined as liver decompensation, hepatocellular carcinoma (HCC) or death.Results: The median followed up was 38.2months. The cumulative incidence of liver decompensation, HCC, or death were similar between two groups. During the Ta-1 combination treatment, the HCC incidence was 1.7% in combination group and 2.1% in ETV group, without new HCC cases developed during week 39 to week 77 in combination group. The virologic response, serologic response, biochemical response was similar between two groups at week 104. Both therapies were well-tolerated.Conclusion: There was no significant difference between two groups in endpoint events, while combination therapy with Ta-1 has a tendency to inhibit the development of HCC.
推荐引用方式
GB/T 7714：

Wu Xiaoning,Shi Yiwen,Zhou Jialing, et al. Combination of entecavir with thymosin alpha-1 in HBV-related compensated cirrhosis: a prospective multicenter randomized open-label study [J].EXPERT OPINION ON BIOLOGICAL THERAPY,2018,18:61-69.
APA：

Wu Xiaoning,Shi Yiwen,Zhou Jialing,Sun Yameng,&You Hong.(2018).Combination of entecavir with thymosin alpha-1 in HBV-related compensated cirrhosis: a prospective multicenter randomized open-label study .EXPERT OPINION ON BIOLOGICAL THERAPY,18:61-69.
MLA：

Wu Xiaoning, et al. "Combination of entecavir with thymosin alpha-1 in HBV-related compensated cirrhosis: a prospective multicenter randomized open-label study" .EXPERT OPINION ON BIOLOGICAL THERAPY 18(2018):61-69.
条目包含文件：

文件类型：PDF,文件大小：

正在加载全文

未找到全文

浏览次数：18  下载次数：0

分享到：

浏览次数：18

下载次数：0

打印次数：0